Selected EMA news, February 2026

New medicines recommended for approval 

• Rezurock (belumosudil) – orphan medicine – conditional approval
  Intended for the treatment of chronic graft-versus-host disease (a condition in which donor cells attack the body’s organs) after a stem-cell transplant

New information on approved medicines

• Iclusig (niraparib / abiraterone acetate) – new indication
  Treatment of leukemia (a type of blood cancer)
• Opdivo (nivolumab) – new indication
  Treatment of several types of cancer, including classical Hodgkin lymphoma

Supply shortages

• Fludarabine (fludarabine)
  Treatment of chronic lymphocytic leukemia, a type of blood cancer